Wealthfront Advisers LLC grew its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 2,090,573.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,314,300 shares of the biotechnology company's stock after purchasing an additional 18,313,424 shares during the period. United Therapeutics comprises about 5.3% of Wealthfront Advisers LLC's portfolio, making the stock its 4th largest position. Wealthfront Advisers LLC owned approximately 41.02% of United Therapeutics worth $6,462,018,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of UTHR. Farther Finance Advisors LLC raised its holdings in United Therapeutics by 673.9% in the third quarter. Farther Finance Advisors LLC now owns 356 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 310 shares during the period. Fiera Capital Corp bought a new stake in shares of United Therapeutics during the third quarter worth $517,000. Axxcess Wealth Management LLC bought a new stake in shares of United Therapeutics during the third quarter worth $435,000. Crossmark Global Holdings Inc. increased its position in shares of United Therapeutics by 20.4% during the third quarter. Crossmark Global Holdings Inc. now owns 3,584 shares of the biotechnology company's stock worth $1,284,000 after acquiring an additional 608 shares in the last quarter. Finally, Meritage Portfolio Management increased its position in shares of United Therapeutics by 9.6% during the third quarter. Meritage Portfolio Management now owns 1,289 shares of the biotechnology company's stock worth $462,000 after acquiring an additional 113 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.
Shares of UTHR traded up $2.67 during midday trading on Wednesday, reaching $307.09. The stock had a trading volume of 723,336 shares, compared to its average volume of 446,209. The firm has a 50 day simple moving average of $351.85 and a 200-day simple moving average of $359.12. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82. The firm has a market cap of $13.79 billion, a PE ratio of 13.49, a P/E/G ratio of 0.97 and a beta of 0.64.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter last year, the firm posted $4.36 EPS. As a group, research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.
Several equities research analysts have recently issued reports on UTHR shares. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. HC Wainwright reissued a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $388.25.
Get Our Latest Research Report on UTHR
In other news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $361.95, for a total transaction of $3,619,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $932,745.15. This trade represents a 79.51 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Nilda Mesa sold 255 shares of the firm's stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 116,464 shares of company stock valued at $42,396,244 in the last quarter. Company insiders own 11.90% of the company's stock.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.